优化耐多药结核病治疗的随机试验。
Randomized trials to optimize treatment of multidrug-resistant tuberculosis.
作者信息
Mitnick Carole D, Castro Kenneth G, Harrington Mark, Sacks Leonard V, Burman William
机构信息
Harvard Medical School, Boston, Massachusetts, United States of America.
出版信息
PLoS Med. 2007 Nov 6;4(11):e292. doi: 10.1371/journal.pmed.0040292.
Abstract
The time is now right for randomized trials of MDR-TB, say the authors, as the expansion of MDR-TB programs provides the setting in which trials can be implemented.
摘要
作者们表示，现在开展耐多药结核病随机试验的时机恰到好处，因为耐多药结核病项目的扩展为实施试验提供了环境。
相似文献
1
Randomized trials to optimize treatment of multidrug-resistant tuberculosis.
PLoS Med. 2007 Nov 6;4(11):e292. doi: 10.1371/journal.pmed.0040292.
2
State of the Art series on drug-resistant tuberculosis: it's time to protect fluoroquinolones.
Int J Tuberc Lung Dis. 2009 Nov;13(11):1319.
3
What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment?
Indian J Med Res. 2019 Mar;149(3):309-312. doi: 10.4103/ijmr.IJMR_579_19.
4
Tuberculosis; opportunities for treatment optimization.
Curr Pharm Des. 2011;17(27):2852. doi: 10.2174/138161211797470219.
5
Extensively drug-resistant tuberculosis, Lesotho.
Emerg Infect Dis. 2008 Jun;14(6):992-3. doi: 10.3201/eid1406.071654.
6
Multidrug-resistant tuberculosis (TB) resistant to fluoroquinolones and streptomycin but susceptible to second-line injection therapy has a better prognosis than extensively drug-resistant TB.
Clin Infect Dis. 2009 Mar 1;48(5):e50-2. doi: 10.1086/597010.
7
Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results.
Clin Infect Dis. 2008 Mar 15;46(6):958-9. doi: 10.1086/528875.
8
Drug-resistant tuberculosis plagues India.
CMAJ. 2016 Mar 15;188(5):322-324. doi: 10.1503/cmaj.109-5235. Epub 2016 Feb 16.
9
Trench warfare in a battle with TB.
Science. 2008 Jul 18;321(5887):362-4. doi: 10.1126/science.321.5887.362.
10
Drug-resistant tuberculosis: reality and potential threat.
Int J Tuberc Lung Dis. 2010 Mar;14(3):255-8.
引用本文的文献
1
Unsuccessful treatment outcome and associated risk factors. A prospective study of DR-TB patients from a high burden country, Pakistan.
PLoS One. 2023 Aug 10;18(8):e0287966. doi: 10.1371/journal.pone.0287966. eCollection 2023.
2
Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape.
PLoS Med. 2019 Mar 22;16(3):e1002767. doi: 10.1371/journal.pmed.1002767. eCollection 2019 Mar.
3
Advances in clinical trial design for development of new TB treatments: A call for innovation.
PLoS Med. 2019 Mar 22;16(3):e1002769. doi: 10.1371/journal.pmed.1002769. eCollection 2019 Mar.
4
Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis.
PLoS One. 2016 Mar 29;11(3):e0151724. doi: 10.1371/journal.pone.0151724. eCollection 2016.
5
Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis.
Clin Infect Dis. 2014 Nov 15;59(10):1364-74. doi: 10.1093/cid/ciu619. Epub 2014 Aug 5.
6
Preventing nosocomial MDR TB transmission in sub Saharan Africa: where are we at?
Glob J Health Sci. 2013 May 15;5(4):200-10. doi: 10.5539/gjhs.v5n4p200.
7
Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.
PLoS Med. 2012;9(8):e1001300. doi: 10.1371/journal.pmed.1001300. Epub 2012 Aug 28.
8
Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis.
Clin Infect Dis. 2012 Aug;55(4):572-81. doi: 10.1093/cid/cis487. Epub 2012 May 21.
9
Induction of mycobacterial resistance to quinolone class antimicrobials.
Antimicrob Agents Chemother. 2012 Jul;56(7):3879-87. doi: 10.1128/AAC.00474-12. Epub 2012 May 7.
10
European union standards for tuberculosis care.
Eur Respir J. 2012 Apr;39(4):807-19. doi: 10.1183/09031936.00203811.
本文引用的文献
1
XDR tuberculosis--implications for global public health.
N Engl J Med. 2007 Feb 15;356(7):656-9. doi: 10.1056/NEJMp068273.
2
XDR-TB in South Africa: no time for denial or complacency.
PLoS Med. 2007 Jan;4(1):e50. doi: 10.1371/journal.pmed.0040050.
3
Surveillance methods and case definition for extensively drug resistant TB (XDR-TB) and relevance to Europe: summary update.
Euro Surveill. 2006 Nov 3;11(11):E061103.1. doi: 10.2807/esw.11.44.03070-en.
4
Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis.
Lancet. 2006 Dec 16;368(9553):2142-54. doi: 10.1016/S0140-6736(06)69863-2.
5
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.
Lancet. 2006 Nov 4;368(9547):1575-80. doi: 10.1016/S0140-6736(06)69573-1.
6
Multidrug-resistant tuberculosis management in resource-limited settings.
Emerg Infect Dis. 2006 Sep;12(9):1389-97. doi: 10.3201/eid1209.051618.
7
Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines.
PLoS Med. 2006 Sep;3(9):e352. doi: 10.1371/journal.pmed.0030352.
8
Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran.
Clin Infect Dis. 2006 Oct 1;43(7):841-7. doi: 10.1086/507542. Epub 2006 Aug 21.
9
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
Lancet. 2006 Aug 5;368(9534):466-75. doi: 10.1016/S0140-6736(06)69154-X.
10
Global incidence of multidrug-resistant tuberculosis.
J Infect Dis. 2006 Aug 15;194(4):479-85. doi: 10.1086/505877. Epub 2006 Jul 12.
Zotero 插件